Inflammation: The Immune System's Emergency Response

What Triggers Inflammation

Inflammation can be initiated by two categories of signals. Pathogen-associated molecular patterns (PAMPs) are molecular structures found on microorganisms but not on host cells: lipopolysaccharide from Gram-negative bacteria, peptidoglycan from bacterial cell walls, double-stranded RNA from replicating viruses, and unmethylated CpG DNA motifs from bacteria. Damage-associated molecular patterns (DAMPs) are molecules released by the body's own injured or dying cells: ATP, uric acid, HMGB1 (a nuclear protein), and fragments of extracellular matrix proteins like hyaluronic acid. Both PAMPs and DAMPs are detected by pattern recognition receptors on tissue-resident immune cells, primarily macrophages, dendritic cells, and mast cells.

The best-characterized pattern recognition receptors are the Toll-like receptors (TLRs), a family of transmembrane proteins that span the cell surface and endosomal membranes. TLR4 on the cell surface detects lipopolysaccharide. TLR3 in the endosome detects double-stranded RNA. TLR9, also endosomal, detects unmethylated CpG DNA. When a TLR binds its ligand, it triggers intracellular signaling cascades through adaptor proteins like MyD88 and TRIF, ultimately activating transcription factors NF-kappaB and IRF3. NF-kappaB drives the expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), chemokines (IL-8, MCP-1), and adhesion molecules. IRF3 drives the production of type I interferons (IFN-alpha and IFN-beta), which are critical for antiviral defense.

Other innate sensors contribute to inflammatory initiation. The NOD-like receptors (NLRs), particularly NLRP3, detect intracellular danger signals and assemble multiprotein complexes called inflammasomes. The NLRP3 inflammasome activates caspase-1, which cleaves pro-IL-1beta and pro-IL-18 into their active forms and can trigger a form of inflammatory cell death called pyroptosis. The cGAS-STING pathway detects cytoplasmic DNA, signaling the presence of either intracellular pathogens or DNA damage, and activates both interferon and NF-kappaB responses. These overlapping detection systems ensure that virtually any type of tissue insult triggers an appropriate inflammatory response.

The Vascular Response

The earliest visible changes during inflammation occur in the local blood vessels. Within seconds of tissue injury, arterioles briefly constrict, then dilate in response to histamine, prostaglandins, and nitric oxide released by mast cells and injured tissue. This vasodilation increases blood flow to the area, producing the redness and warmth that are two of the cardinal signs of inflammation.

Simultaneously, inflammatory mediators increase the permeability of postcapillary venules, the smallest veins in the microcirculation. Endothelial cells contract and separate, widening the gaps between them. Plasma proteins, including complement components, antibodies, and clotting factors, leak through these gaps into the surrounding tissue. Water follows the proteins osmotically, producing edema, the swelling that is the third cardinal sign. This protein-rich fluid, called inflammatory exudate, is fundamentally different from the protein-poor fluid (transudate) that accumulates in non-inflammatory edema. The exudate delivers complement proteins and antibodies directly to the site of infection, enabling pathogen opsonization and destruction in the tissues.

The increased vascular permeability also slows blood flow in the affected area, a phenomenon called stasis. As flow slows, red blood cells stack together (rouleaux formation), and white blood cells move from the central stream of blood toward the vessel walls. This margination brings leukocytes into contact with the endothelium, setting the stage for their exit from the bloodstream.

Leukocyte Recruitment

The migration of immune cells from the bloodstream into infected or damaged tissue is a multi-step process called the leukocyte adhesion cascade. Each step involves specific molecular interactions between the leukocyte and the vascular endothelium, ensuring that immune cells are recruited precisely to sites where they are needed.

The first step is rolling. Endothelial cells activated by inflammatory cytokines express selectins (P-selectin and E-selectin) on their surface. These selectins bind loosely to carbohydrate ligands on passing leukocytes, slowing them down and causing them to roll along the vessel wall like a ball bouncing on a surface. P-selectin appears within minutes, stored in preformed granules called Weibel-Palade bodies; E-selectin takes 1 to 2 hours, requiring new gene expression.

Rolling leukocytes encounter chemokines displayed on the endothelial surface, particularly IL-8 (CXCL8), which is the primary chemoattractant for neutrophils. Chemokine binding activates integrins on the leukocyte surface, switching them from a low-affinity to a high-affinity conformation. This is the activation step. The activated integrins (primarily LFA-1 and Mac-1) then bind firmly to their ligands on the endothelium (ICAM-1 and ICAM-2), arresting the leukocyte and stopping its rolling. This firm adhesion step is critical: without it, leukocytes continue rolling past the site of inflammation without stopping.

After firm adhesion, the leukocyte squeezes between endothelial cells and crosses the basement membrane in a process called transmigration or diapedesis. PECAM-1 (CD31), expressed on both leukocytes and endothelial cell junctions, facilitates this passage. Once in the tissue, the leukocyte follows chemokine concentration gradients toward the source of infection, a process called chemotaxis. Neutrophils are typically the first cells to arrive, within 30 to 60 minutes. Monocytes follow over the next several hours, differentiating into macrophages upon entering the tissue.

Inflammatory Mediators

The inflammatory response is orchestrated by a complex network of signaling molecules that amplify, sustain, and eventually resolve the response. These mediators can be broadly categorized by their source and function.

Cell-derived mediators include histamine (from mast cells and basophils, causing vasodilation and increased permeability), prostaglandins (from arachidonic acid via the cyclooxygenase pathway, causing vasodilation, pain, and fever), leukotrienes (from arachidonic acid via the lipoxygenase pathway, causing bronchoconstriction and increased permeability), and platelet-activating factor (PAF, which activates platelets and leukocytes and increases vascular permeability). Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin work by inhibiting cyclooxygenase enzymes, reducing prostaglandin production and thereby decreasing pain, swelling, and fever.

Cytokines are protein mediators that coordinate the inflammatory response at multiple levels. TNF-alpha, produced primarily by macrophages, activates endothelial cells, promotes leukocyte adhesion, stimulates acute-phase protein production by the liver, and causes fever by acting on the hypothalamus. IL-1beta has overlapping functions with TNF-alpha and is a potent pyrogen. IL-6 drives the acute-phase response, stimulating the liver to produce C-reactive protein (CRP), fibrinogen, and serum amyloid A, proteins that enhance pathogen opsonization and blood clotting at the site of infection. IL-8 is the principal neutrophil chemoattractant. IL-12 bridges innate and adaptive immunity by promoting Th1 differentiation and NK cell activation.

Plasma-derived mediators include the complement system (generating C3a, C4a, and C5a anaphylatoxins that promote inflammation and C3b opsonin), the kinin system (generating bradykinin, which causes vasodilation, increased permeability, and pain), and the coagulation cascade (generating fibrin that walls off the infected area and traps bacteria). These plasma protein systems amplify the initial inflammatory signal through enzymatic cascades, producing effects far larger than the original stimulus.

Acute vs Chronic Inflammation

Acute inflammation is a rapid, short-lived response that typically resolves within hours to days once the offending stimulus is eliminated. The resolution phase is not simply the absence of inflammatory signals but an active, coordinated process driven by specialized pro-resolving mediators (SPMs). These include lipoxins, resolvins, protectins, and maresins, all derived from omega-3 and omega-6 fatty acids. SPMs inhibit neutrophil recruitment, promote macrophage phagocytosis of apoptotic cells and debris (efferocytosis), and stimulate tissue repair and regeneration. Anti-inflammatory cytokines, particularly IL-10 and TGF-beta, further dampen the inflammatory response and promote healing.

Chronic inflammation occurs when the inflammatory response fails to resolve. This can happen because the stimulus persists (as in chronic infections like tuberculosis or Helicobacter pylori gastritis), because the immune system mounts a sustained response to harmless antigens (as in autoimmune diseases), or because ongoing tissue injury produces continuous DAMP release (as in obesity-related inflammation of adipose tissue). Chronic inflammation is characterized by the simultaneous presence of tissue destruction, repair, and ongoing inflammation, a pattern that distinguishes it from the sequential destruction-then-repair course of acute inflammation.

The cellular infiltrate in chronic inflammation differs from that in acute inflammation. While acute inflammation is dominated by neutrophils, chronic inflammation is characterized by macrophages, lymphocytes, and plasma cells. Macrophages in chronic inflammatory lesions are continuously activated, producing reactive oxygen species, proteases, and cytokines that damage surrounding tissue. Fibroblasts proliferate and deposit collagen, leading to fibrosis, the replacement of functional tissue with scar tissue.

Inflammation and Disease

Chronic inflammation is now recognized as a major contributor to many of the most prevalent and serious diseases of modern life. Atherosclerosis, the leading cause of heart attacks and strokes, is fundamentally an inflammatory disease of the arterial wall. Oxidized LDL cholesterol triggers macrophage recruitment and activation, creating foam cells that form the core of atherosclerotic plaques. Inflammatory cytokines destabilize plaques, making them prone to rupture, which triggers the blood clot that causes a heart attack or stroke. The success of anti-inflammatory therapies in reducing cardiovascular events has confirmed inflammation's causal role.

Type 2 diabetes is associated with chronic low-grade inflammation of adipose tissue. Enlarged fat cells secrete inflammatory cytokines, particularly TNF-alpha and IL-6, which impair insulin signaling in muscle and liver cells, contributing to insulin resistance. Alzheimer's disease involves neuroinflammation, with microglia (brain macrophages) becoming chronically activated in response to amyloid-beta plaques and tau tangles. Cancer is both promoted by chronic inflammation and itself triggers inflammatory responses: the tumor microenvironment contains macrophages, neutrophils, and inflammatory mediators that can promote tumor growth, angiogenesis, and metastasis.

Understanding the mechanisms of inflammation has led to some of the most important therapeutic advances in modern medicine. Corticosteroids suppress inflammation broadly by inhibiting NF-kappaB signaling. Biologic therapies target specific cytokines: anti-TNF antibodies (adalimumab, infliximab) have transformed the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis. Anti-IL-6 antibodies (tocilizumab) are used in rheumatoid arthritis and were deployed during the COVID-19 pandemic to treat cytokine storm. JAK inhibitors (tofacitinib, baricitinib) block intracellular cytokine signaling pathways and are used for rheumatoid arthritis, ulcerative colitis, and atopic dermatitis.